Nicholas P. McAndrew

Author

University of California, Los Angeles ORCID

Also Known As

McAndrew, Nicholas, N. McAndrew, N. Mcandrew, N.P. McAndrew, Nicholas McAndrew, Nicholas P McAndrew, Nicholas P. McAndrew, Nicholas Patrick McAndrew

Publications

977

Citations

H-Index

Concepts

All Affiliations

University of California, Los Angeles Massachusetts General Hospital University of Pennsylvania UCLA Jonsson Comprehensive Cancer Center Cancer Center of Kansas

About

Nicholas P. McAndrew is an author at University of California, Los Angeles specializing in cancer therapeutics, breast cancer, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	108
2	Pharmacology	3	3	108
3	Immunology	2	2	66
4	Pathology	2	2	71
5	Health Sciences	1	1	37

Nicholas P. McAndrew

Publications

558

Citations

H-Index

Page 1

	Year	Citations
Ribociclib plus Endocrine Therapy in Early Breast Cancer Dennis J. Slamon, Oleg Lipatov, Zbigniew Nowecki, New England Journal of Medicine	2024	296
Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer Amy S. Clark, Nicholas P. McAndrew, Andrea B. Troxel, Clinical Cancer Research	2019	45
Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer. Nicholas P. McAndrew, Angela DeMichele PubMed Surgical OncologyBreast OncologyMedicinePharmacologyPathology	2018	42
Early treatment-related neutropenia predicts response to palbociclib Nicholas P. McAndrew, Mark A. Dickson, Amy S. Clark, British Journal of Cancer	2020	38
Effects of systemic inflammation on relapse in early breast cancer Nicholas P. McAndrew, Lisa N. Bottalico, Clementina Mesaros, npj Breast Cancer	2021	37
TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer. Sara A. Hurvitz, Lisa S. Wang, David W. Chan, Journal of Clinical Oncology Breast OncologyTps623 BackgroundMedicineImmunologyClinical Trials	2022	37
Abstract GS2-03: GS2-03 TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer Aditya Bardia, Sara A. Hurvitz, Michael F. Press, Cancer Research Breast OncologyImmunologyPathologyDermatologyImmunotherapy	2023	29
Preclinical and clinical activity of DZD1516, a full blood–brain barrier-penetrant, highly selective HER2 inhibitor Jian Zhang, Nicholas P. McAndrew, Xiaojia Wang, Breast Cancer Research	2023	12
TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer. Sara A. Hurvitz, Parvin F. Peddi, Merry Tetef, Journal of Clinical Oncology	2021	11
Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial. Denise A. Yardley, Michael Untch, Carlos H. Barrios, Journal of Clinical Oncology	2024	11

Page 1